NCT03243019

Efficacy of Rapamycin in the Treatment of Cervico-facial Lymphatic Malformations

Evaluation of the Efficacy of Rapamycin in the Treatment of Cervico-facial Lymphatic Malformations of Poor Prognosis

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 28 (estimated)
• Sponsor: University Hospital, Lille · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy of Rapamycin in extended cervicofacial lymphatic malformations in pediatric patients. Rapamycin is administered oral for a 6 month period. The success rate is determined by volume reduction superior to 1/5e of the initial volume measured by MRI, impact on QOL and reduction of bleeding in case of mucosal involvement.

Conditions

• Lymphatic Malformation
• Pediatric

Interventions

Type	Name	Description
DRUG	rapamycin	oral administration
DEVICE	MRI	cervicofacial MRI
BIOLOGICAL	Rapamycin dosage	Biological dosage of Rapamycin level

Timeline

• Start date: 2018-06-25
• Primary completion: 2026-02-01
• Completion: 2026-02-01
• First posted: 2017-08-08
• Last updated: 2025-12-16

Locations

2 sites across 1 country: France